Chonluten
⚠️ Structural Separation Notice
The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.
Synthetic tripeptide (Glu-Asp-Gly) bioregulator proposed to support respiratory and GI mucosal function via bronchial and GI epithelial gene regulation.
Methodological Note: >95% of published research on this peptide originates from the Khavinson bioregulation group (Institute of Bioregulation and Gerontology, St. Petersburg). Independent replication by Western laboratories is lacking. All evidence should be interpreted with this single-group limitation in mind.
Quick Facts
| Property | Value |
|---|---|
| Also Known As | EDG tripeptide, Glu-Asp-Gly |
| Category | Gastrointestinal / Respiratory / Khavinson Bioregulator |
| Sequence | Glu-Asp-Gly (EDG, 3 amino acids) |
| Molecular Weight | ~319 Da |
| Molecular Formula | C9H14N2O7 |
| PubChem CID | N/A — research peptide |
| Administration | SubQ / Oral |
| Typical Dose Range | 10-20 mcg/day (from Khavinson protocols) |
| Half-Life | Very short (minutes; typical of tripeptides) |
| Storage | Lyophilized: -20C long-term; 2-8C short-term. Reconstituted: 2-8C for 2-4 weeks |
| FDA Status | NOT FDA-approved. Approved in Russia as bioregulator; no Western regulatory approval |
| WADA Status | Prohibited under S0 (non-approved substances) |
Mechanism of Action
Chonluten (Glu-Asp-Gly) is a synthetic tripeptide developed by the Khavinson group, derived from the amino acid analysis of bronchial/respiratory epithelial tissue extracts. It is proposed to regulate gene expression in mucosal epithelial cells of both the respiratory tract and gastrointestinal system.
In an animal study using rats with experimentally induced obstructive lung pathology, Chonluten had a modulating effect on the morphofunctional state of bronchial epithelium (PMID: 26468022). The peptide reduced pathological changes in bronchial epithelial structure and promoted restoration of normal epithelial architecture. The stress-protective effect was associated with regulation of c-Fos gene, heat shock protein gene HSP70, antioxidant enzyme genes (SOD), COX-2, and TNF-alpha gene expression.
In vitro studies using the THP-1 monocyte/macrophage cell line demonstrated that Chonluten (EDG) inhibited TNF production in monocytes exposed to pro-inflammatory bacterial lipopolysaccharide (LPS) (PMID: 35408963), supporting an anti-inflammatory mechanism.
Oral administration of the EDG tripeptide has been reported effective for treating bronchopulmonary pathology including chronic obstructive pulmonary disease and chronic bronchitis with asthmatic component, according to Russian clinical literature (not indexed as controlled trials in PubMed).
Key Research Areas
- Bronchial epithelial repair — Restoration of epithelial architecture in obstructive lung models
- Anti-inflammatory activity — TNF inhibition in LPS-stimulated monocytes
- Gene expression modulation — Regulation of c-Fos, HSP70, SOD, COX-2, TNF-alpha
- COPD/bronchitis — Reported clinical use in Russian respiratory medicine
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Human RCTs | 0 | No randomized controlled trials |
| Human observational | 0 | Russian clinical reports only (not PubMed-indexed as trials) |
| Animal in vivo | 1 | Obstructive lung pathology model in rats |
| In vitro | 1 | THP-1 cell study (anti-TNF) |
| Systematic reviews | 1 | Khavinson self-review (2021) |
Clinical Applications
- Gut Health — Proposed GI mucosal support (no clinical evidence)
- Immune Support — Anti-inflammatory mucosal effects (preclinical only)
Protocols Using This Peptide
- No established clinical protocols. Used in Khavinson bioregulation research protocols only.
Ageless Peps Products
- APWS-Chonluten-Vial — Chonluten Vial, wholesale only
Dosing Reference
Research Dosing Ranges (from literature)
| Route | Dose Range | Frequency | Duration | Source |
|---|---|---|---|---|
| SubQ | 10-20 mcg | Daily | 10-20 days | Khavinson protocols |
| Oral | 10-20 mcg | Daily | 10-20 days | Khavinson protocols |
Cycling
Khavinson protocols typically recommend 10-20 day treatment courses with 1-3 month intervals. No independent validation exists.
Contraindications & Safety
- Contraindications: Unknown — no systematic safety studies
- Common side effects: Unknown — no human clinical data from controlled trials
- Drug interactions: Unknown — no interaction studies
- Pregnancy/nursing: Contraindicated (no safety data)
- Special populations: No data available
Synergistic Combinations
Per Khavinson protocols (unvalidated):
- Crystagen + Chonluten — Immune + mucosal support
- Vilon + Chonluten — Thymic immune + respiratory support
Related Research
| PMID | Title | Year | Study Type |
|---|---|---|---|
| 26468022 | Peptide Therapy on Bronchial Epithelium in Obstructive Lung Pathology | 2015 | Animal in vivo |
| 34834147 | Peptide Regulation of Gene Expression: A Systematic Review | 2021 | Systematic Review |
| 35408963 | Peptides Regulating Proliferative Activity in THP-1 Cell Line | 2022 | In vitro |
References
- PMID 26468022 — Bronchial epithelium in obstructive lung model
- PMID 34834147 — Systematic review of peptide gene regulation
- PMID 35408963 — THP-1 cell line TNF inhibition
Related
#peptide #gastrointestinal #khavinson-bioregulator #subq